The drug known as "the pink pill", or the "female Viagra" has been unanimously rejected by an FDA panel of advisors. The panel has decided that the benefits do not outweigh adverse effects like depression, fainting and fatigue.
This is not the final word on the drug flibanerin. The FDA will make its decision at a later time.
Flibanerin affects serotonin and other chemicals in the brain. It was initially being researched for the treatment of depression.
Pfizer had tested Viagra on women without great success. Later, research on hormones was hoped to be the key to finding a product that would raise female libido.
Professor Kim Wallen of Emory University is dubious about the approaches taken thus far. Nevertheless he thinks a pharmaceutical solution to low female libido may still be possible.
"But he says the industry's search for a magic pill oversimplifies the problem. Sexuality is influenced by so many factors — including physical health, quality of relationships and lifestyle — that it's unrealistic to assume a drug could address millions of different cases of low libido."